Table 1.
Baseline Characteristics of the Intention-to-Treat Population*
| Characteristic | Omega-3 Fatty Acids (n = 180) |
Placebo (n = 178) |
P-Value |
|---|---|---|---|
| Demographics | |||
| Age - yr | 60 ± 10 | 58 ± 10 | 0.22 |
| Female sex – no. (%) | 32 (18) | 38 (21) | 0.39 |
| White race – no. (%) | 143 (81) | 146 (82) | 0.68 |
| Body mass index [kg/m2] | 29 ± 5.4 | 29 ± 5.6 | 0.92 |
| Body surface area [m2] | 2.0 ± 0.23 | 2.0 ± 0.22 | 0.82 |
| Heart rate [bpm]† | 64 (60, 71) | 66 (60, 71) | 0.26 |
| Systolic BP [mm Hg] | 121 ± 15 | 120 ± 16 | 0.73 |
| Diastolic BP [mm Hg] | 70 ± 10 | 70 ± 11 | 0.62 |
| Enrolling sites – no. (%) | 0.57 | ||
| Brigham and Women’s | 115 (64) | 109 (61) | |
| Massachusetts General | 38 (21) | 33 (19) | |
| Beth Israel Deaconess | 27 (15) | 36 (20) | |
| Index Event | |||
| STEMI – no. (%) | 102 (57) | 105 (59) | 0.66 |
| Anterior – no. (%) | 48 (27) | 48 (27) | 1.00 |
| TIMI 3 flow achieved – no. (%) | 145 (91) | 156 (91) | 0.99 |
| Troponin-T (peak) [µmol/L]† | 2.8 (0.9, 9.1) | 3.4 (0.8, 10.4) | 0.72 |
| Creatine kinase (peak) [U/L]† | 786 (330, 1608) | 693 (296, 1621) | 0.74 |
| Creatine kinase MB (peak) [U/L] | 61 (26, 152) | 61 (21, 148) | 0.97 |
| Hematocrit (%)† | 39 (36, 42) | 40 (36, 43) | 0.10 |
| Cardiovascular Disease History | |||
| Angina – no. (%) | 44 (25) | 36 (20) | 0.30 |
| Peripheral vascular disease – no. (%) | 7 (4) | 13 (7) | 0.17 |
| Myocardial infarction – no. (%) | 22 (12) | 14 (8) | 0.16 |
| CABG – no. (%) | 24 (13) | 11 (6) | 0.02 |
| PCI – no. (%) | 24 (13) | 23 (13) | 0.91 |
| Congestive heart failure – no. (%) | 4 (2) | 6 (3) | 0.52 |
| NYHA class – no. (%) | 0.37 | ||
| 1 | 167 (94) | 160 (90) | |
| 2 | 10 (5.5) | 17 (9.5) | |
| 3 | 1 (0.5) | 1 (0.5) | |
| Hypercholesterolemia – no. (%) | 134 (75) | 120 (67) | 0.10 |
| Diabetes mellitus – no. (%) | 46 (26) | 45 (25) | 0.90 |
| Hypertension – no. (%) | 118 (66) | 112 (63) | 0.51 |
| Smoker (current) – no. (%) | 23 (13) | 36 (20) | 0.06 |
| Medications | |||
| Dual antiplatelet – no. (%)γ | 174 (98) | 174 (98) | 1.00 |
| Beta-blocker – no. (%) | 163 (92) | 164 (92) | 0.85 |
| Statin – no. (%) | 172 (97) | 171 (96) | 0.78 |
| Calcium channel blocker – no. (%) | 16 (9) | 10 (6) | 0.22 |
| ACE inhibitor or ARB – no. (%) | 134 (75) | 127 (71) | 0.40 |
| Aldosterone antagonists – no. (%) | 0 (0) | 1 (1) | 0.91 |
| Insulin – no. (%) | 18 (10) | 15 (8) | 0.57 |
| Nitroglycerin – no. (%) | 25 (14) | 19 (11) | 0.33 |
| Diuretics – no. (%) | 25 (14) | 18 (10) | 0.33 |
ACE denotes angiotensin converting enzyme, ARB angiotensin receptor blocker, BP blood pressure, NYHA New York Heart Association, PCI percutaneous coronary intervention, and STEMI ST-elevation myocardial infarction. Beta-blocker is defined as β-adrenergic–receptor antagonist, and statin is defined as hydroxymethylglutaryl-coenzyme A reductase inhibitor.
Continuous data are means ± SD if normally distributed, otherwise median (25th, 75th percentile).
γ
Dual antiplatelet therapy included aspirin plus either clopidogrel or prasugrel.
†
Natural logarithm transformation was used to improve normality and/or homoscedasticity of residuals, prior to performing Student’s t-tests.